METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for men with Tough-to-Treat prostate cancer: drug combo trial opens
Disease control Recruiting nowThis study tests whether adding a new drug called SX-682 to the standard drug apalutamide can help men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial will enroll 78 men and aims to find a safe, effective dose and see i…
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated May 17, 2026 07:04 UTC
-
Could custom dosing of prostate cancer radiation therapy improve treatment?
Disease control Recruiting nowThis study tests whether giving a personalized dose of a radioactive drug (177Lu-PSMA-617) based on kidney radiation exposure is safer and allows higher doses than the standard fixed dose. About 60 men with advanced prostate cancer that no longer responds to hormone therapy will …
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Jean-Mathieu Beauregard • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new treatment called TmPSMA-02 for men with metastatic castrate-resistant prostate cancer (mCRPC) that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified to better recognize and attack cancer cells. …
Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 11, 2026 20:40 UTC